Condition
AL Amyloidosis (AL)
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 2 (1)
Trial Status
Recruiting1
Enrolling By Invitation1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07335887Phase 2Not Yet RecruitingPrimary
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
NCT07103863Enrolling By InvitationPrimary
Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
NCT07085559Early Phase 1Recruiting
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Showing all 3 trials